Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents?

Joint Bone Spine. 2004 Jul;71(4):257-60. doi: 10.1016/j.jbspin.2004.01.002.
No abstract available

Publication types

  • Editorial
  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antirheumatic Agents / administration & dosage*
  • Dose-Response Relationship, Drug
  • Humans
  • Rheumatic Diseases / therapy*
  • Spondylarthritis / therapy*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha